ProCE Banner Activity

CME

CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Individualizing Therapeutic Decisions to Improve Patient Outcomes

Multimedia
Watch this on-demand webcast of a live CCO webinar where global experts discuss the latest data on CDK4/6 inhibitors in the treatment of patients with early-stage HR+/HER2- breast cancer.

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: July 21, 2021

Expiration: July 20, 2022

No longer available for credit.

Share

Faculty

Javier Cortes

Javier Cortes, MD, PhD

Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain

Stephen Raffanti

Stephen Raffanti, MD, MPH

Associate Professor of Medicine
Division of Infectious Disease
Vanderbilt University School of Medicine
Chief Medical Officer
Comprehensive Care Center
Nashville, Tennessee

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Target Audience

This educational curriculum is intended for medical oncologists, breast surgeons, and other healthcare professionals involved in the treatment of breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Understand the medical need for new targeted therapies to treat patients with HR+/HER2- EBC and a higher risk of recurrence along with the underlying factors affecting the decision-making process for patients and potential barriers to adoption of novel treatment options
  • Appraise current/emerging published data and consensus-based guidelines to inform the use of biomarkers and genomic classifiers to assess risk of recurrence

  • Individualize the selection of systemic therapy for appropriate patients with HR+/HER2- EBC to include CDK4/6 inhibitors with or without endocrine therapy
  • Develop strategies to anticipate, monitor, and manage adverse events with current and emerging therapies for HR+/HER2- EBC to improve adherence and optimize outcomes

  • Identify patients with HR+/HER2- EBC eligible for enrollment on ongoing clinical studies investigating novel therapies

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Javier Cortes, MD, PhD

Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain

Javier Cortes, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Athenex, Bioasis, Biothera, Boehringer Ingelheim, Celgene, Cellestia, Clovis Oncology, Daiichi Sankyo, Erytech, GlaxoSmithKline, Leuko, Lilly, Kyowa Kirin, Merck Sharp & Dohme, Merus, Polyphor, Roche, Seattle Genetics, and Servier; has received funds for research support from Ariad, AstraZeneca, Baxalta GmbH/Servier Affaires, Bayer, Eisai, F. Hoffmann-La Roche, Guardant, Merck Sharp & Dohme, Pfizer, Piqur, Puma, and Roche; has received fees for non-CME/CE services from Celgene, Daiichi Sankyo, Eisai, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Samsung Bioepis; has received other financial or material support from Daiichi Sankyo, Eisai, Novartis, Pfizer, and Roche; and has ownership interest in MedSIR.

Stephen Raffanti, MD, MPH

Associate Professor of Medicine
Division of Infectious Disease
Vanderbilt University School of Medicine
Chief Medical Officer
Comprehensive Care Center
Nashville, Tennessee

Stephen R. D. Johnston, MA, FRCP, PhD, has disclosed that he has received consulting fees from AstraZeneca, Lilly, Novartis, Pfizer, and Puma Biotechnology; funds for research support from AstraZeneca, Lilly, Novartis, Pfizer, Puma, and Roche/ Genentech; and fees for non-CME/CE services from AstraZeneca, Eisai, Novartis, Pfizer, and Roche/Genentech.

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Sara Tolaney, MD, MPH, has disclosed that she has received funds for research support paid to her institution AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech/Roche, Immunomedics/Gilead Sciences, Lilly, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, and Seattle Genetics and consulting fees from 4D Pharm, AstraZeneca, Athenex, Bristol-Myers Squibb, Certara, Cytom, Daiichi Sankyo, Eisai, Ellipses, Genentech/Roche, Immunomedics/Gilead, Kyowa Kirin, Lilly, Merck, Mersana, Nanostring, Nektar, Novartis, Odonate, OncoPep, Pfizer, Puma, Samsung Bioepsis, Sanofi, and Seattle Genetics.

Staff Disclosure

Staff

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace has no relevant conflicts of interest to report.

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 21, 2021, through July 20, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this educational curriculum is to improve the knowledge, competence, and performance of learners to plan individualized treatment for patients with HR+/HER2- EBC.